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Abstract
Congenital hyperinsulinism (HI) is an inappropriate insulin secretion by the pancreatic b-cells secondary to various
genetic disorders. The incidence is estimated at 1/50, 000 live births, but it may be as high as 1/2, 500 in countries
with substantial consanguinity. Recurrent episodes of hyperinsulinemic hypoglycemia may expose to high risk of
brain damage. Hypoglycemias are diagnosed because of seizures, a faint, or any other neurological symptom, in
the neonatal period or later, usually within the first two years of life. After the neonatal period, the patient can
present the typical clinical features of a hypoglycemia: pallor, sweat and tachycardia. HI is a heterogeneous
disorder with two main clinically indistinguishable histopathological lesions: diffuse and focal. Atypical lesions are
under characterization. Recessive ABCC8 mutations (encoding SUR1, subunit of a potassium channel) and, more
rarely, recessive KCNJ11 (encoding Kir6.2, subunit of the same potassium channel) mutations, are responsible for
most severe diazoxide-unresponsive HI. Focal HI, also diazoxide-unresponsive, is due to the combination of a
paternally-inherited ABCC8 or KCNJ11 mutation and a paternal isodisomy of the 11p15 region, which is specific to
the islets cells within the focal lesion. Genetics and
18F-fluoro-L-DOPA positron emission tomography (PET) help to
diagnose diffuse or focal forms of HI. Hypoglycemias must be rapidly and intensively treated to prevent severe and
irreversible brain damage. This includes a glucose load and/or a glucagon injection, at the time of hypoglycemia,
to correct it. Then a treatment to prevent the recurrence of hypoglycemia must be set, which may include
frequent and glucose-enriched feeding, diazoxide and octreotide. When medical and dietary therapies are
ineffective, or when a focal HI is suspected, surgical treatment is required. Focal HI may be definitively cured when
the partial pancreatectomy removes the whole lesion. By contrast, the long-term outcome of diffuse HI after
subtotal pancreatectomy is characterized by a high risk of diabetes, but the time of its onset is hardly predictable.
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Definition
Congenital hyperinsulinism (HI) comprises a group of
different genetic disorders with the common finding of
recurrent episodes of hyperinsulinemic hypoglycemias
due to an inappropriate secretion of insulin by the pan-
creatic b-cells [1-5]. This definition excludes insulin
related hypoglycemia due to insulin resistance syn-
dromes and to acquired hyperinsulinemic hypoglycemias
(see differential diagnosis below).
The former names of HI are now obsolete: “idiopathic
hypoglycemia of infancy”, “nesidioblastosis”, “persistent
hyperinsulinemic hypoglycemia of infancy, PHHI”,
because HI is genetic not idiopathic, nesidioblastosis
was found to be a normal feature of the pancreas in
early infancy, and HI can persist from infancy to adult-
hood. The denomination “Congenital hyperinsulinism”
should be preferred.
Epidemiology
The estimated incidence of HI is 1/50, 000 live births
(up to 1/2, 500 in Saudi Arabia because of a high rate of
consanguinity). Mutations in the ABCC8 and KCNJ11
genes are the most common causes of HI and account
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sive patients [6]), whereas mutations have been identi-
fied on six other genes in approximately 5 to 10% of the
cases. The genetic etiology for the remaining 45-55% of
patients is still unknown [7]. Fifty five to sixty percent
of diazoxide-unresponsive HI are focal forms, whereas
40-45% are diffuse forms, in western countries [6].
Clinical presentation
Hypoglycemia is the main feature of HI and gives a high
risk of seizures and brain damage. Symptoms revealing
hypoglycemia are various and depend on the severity of
hypoglycemia and the age of the patient, ranging from
asymptomatic hypoglycemia revealed by routine blood
glucose monitoring to life-threatening hypoglycemic
coma or status epilepticus.
During the neonatal period, severe hypoglycemias
are revealed by seizures in half the patients. Most
affected newborns are macrosomic at birth with a mean
birth-weight of 3.7 kg and approximately 30% are deliv-
ered by cesarean section [8]. Hypoglycemia is perma-
nent, both in the fasting and the post-prandial states.
T h em e a nr a t eo fi n t r a v e n o u sg l u c o s ea d m i n i s t r a t i o n
required to maintain plasma glucose above 3 mmol/l
may be as high as 17 mg/kg.min [8]. A mild hepatome-
galy is frequently found. Low cortisol and growth hor-
mone levels can be observed at the time of
hypoglycemia, but these hormonal abnormalities are not
diagnostic for either cortisol or GH insufficiency and
they will resolve within weeks. Neonatal hypoglycemias,
when severe (coma, seizures) or prolonged, expose to a
poor neurological outcome. Hypoglycemias are usually
diazoxide-unresponsive, except in case of perinatal
stress-induced transient hyperinsulinism, syndromic HI
and HI related to HNF4A and GLUD1 mutations (see
below).
During infancy and childhood, hypoglycemias may
be diagnosed between one and twelve months of age, in
half the patients, or even later in life, sometimes because
of a delayed diagnosis. The presenting symptoms before
1 year of age are seizures, episodes of drowsiness or
excitability. After 1 year, the symptoms are typical of
hypoglycemia: pallor, faint, tachycardia and sweating,
seizures. Macrosomia at birth is often reported (mean
birth-weight around 3.6 kg) [8]. The characteristics of
hypoglycemia are similar, although lower rates of intra-
venous glucose are required to maintain normal plasma
glucose levels (12-13 mg/kg.min when the patient is less
than 1 year old at diagnosis).
Syndromic HI are usually diazoxide-responsive. The
onset of hypoglycemia is usually early at birth, at a time
the dysmorphic features may be barely apparent, so that
careful examination and systematic diagnostic tests
should be performed (e.g. CDG syndrome). Conversely,
asymptomatic hypoglycemia may also be screened dur-
ing the follow-up of a known syndromic patient. The
specific clinical features of these syndromic HI are listed
in Table 1.
Etiopathogenesis
Congenital hyperinsulinism is a primary defect of the
pancreatic b-cell leading to an inappropriate secretion of
insulin [5]. Insulin lowers plasma glucose both by inhi-
biting glycogenolysis and gluconeogenesis and by stimu-
lating glucose uptake in muscle and adipocytes. This
explains two main and characteristic clinical findings of
neonatal HI: the high glucose infusion rate required to
prevent hypoglycemia and the responsiveness of hypo-
glycemia to exogenous glucagon, since glucagon stimu-
lates glycogen breakdown and gluconeogenesis.
Moreover, insulin inhibits lipolysis, thus preventing
compensatory ketogenesis to protect the brain from
hypoglycemia.
Classification of isolated HI
1. Pathological classification
We present here a classification according to the etio-
pathogenic process.
Channelopathies affect the subunits of a KATP chan-
nel set through the plasma membrane of the b-cells.
Both subunits can be affected: the sulfonylurea receptor
(SUR1) encoded by the ABCC8 gene and the inward-
rectifying potassium channel (Kir6.2) encoded by the
KCNJ11 gene. When closed, the KATP channel depo-
larizes the plasma membrane leading to insulin secre-
tion. As diazoxide is a KATP channel agonist, the
patients are diazoxide-unresponsive when the defect in
ABCC8 or KCNJ11 abolishes the function of this chan-
nel. In this group of HI, two clinically indistinguishable
histopathological lesions have been described: the focal
and the diffuse HI (both mostly resistant to diazoxide).
Focal HI is sporadic, while diffuse HI is autosomal-
recessively inherited [9-15] or more rarely dominantly-
inherited [16].
Enzymes anomalies or other metabolic defects
involve glucokinase encoded by the GCK gene [17], glu-
tamate dehydrogenase or GDH encoded by GLUD1
gene (HI/HA syndrome) [18], short-chain L-3-hydroxya-
cyl-CoA dehydrogenase (SCHAD) encoded by HADH
gene [19], and more recently the SLC16A1 gene encod-
ing a monocarboxylate transporter (MCT1) that med-
iates the movement of lactate and pyruvate across cell
membranes and causes physical exercise-induced hypo-
glycemia (the patients suffer from hypoglycemic symp-
toms only when performing strenuous physical exercise)
[20] and the UCP2 gene encoding the UCP2 protein
which regulates the protons leak across the inner mito-
chondrial membrane [21]. UCP2 (mitochondrial
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in two unrelated children with neonatal-onset congenital
HI and hypoglycemia which were diazoxide-responsive
[21]. UCP2 induces a regulated leak of protons across
the inner mitochondrial membrane and uncouples mito-
chondrial oxidative metabolism from ATP synthesis
[22]. Consequently, ATP cells content decreases and
insulin secretion as well. UCP2 over-expression in rat
isolated pancreatic islet cells decreases the ATP content
and inhibits glucose-stimulated insulin secretion. Con-
versely, UCP2 knockout mice exhibit hyperinsulinemic
hypoglycemia [23].
All these types of HI affect the ATP/ADP ratio within
the b-cells, which determines the opened or the closed
status of the KATP channel. They are diffuse forms of HI
and diazoxide-responsive with the exception of GCK
mutations which can be diazoxide-unresponsive in some
patients.
A transcription factor defect, involving the hepato-
cyte nuclear factor 4 alpha gene (HNF4A), is also
responsible of HI. The target genes of HNF4A are var-
ious and not fully explored. HNF4A may promote
Kir6.2 expression [24], have an interaction with the per-
oxysome proliferators-activated receptor- a (PPAR-a)
which has a known role on cellular lipid metabolism.
PPAR-a null mice exhibit a fasting hyperinsulinemic
hypoglycemia phenotype [25]. This dominantly-inherited
HI, occurring at birth, is diazoxide-responsive and has a
diffuse pattern at the histopathological examination.
Relatives may present MODY 1 type diabetes.
2. Histological classification
Focal forms are usually restricted to a small area (2.5 to
7.5 mm in diameter) of the pancreas but very large focal
forms were also observed. The focal lesions are made of
large endocrine cells because of their large cytoplasm
with dispersed abnormal nuclei of irregular and angular
shape that are more than 3 to 5 times the size of nearby
acinar nuclei taken as controls (Figure 1). Most of the
time, a focal lesion contains multiple adjacent abnormal
lobules frequently intermingled with or surrounded by
acinar foci. Somatostatin detection by immunohisto-
chemistry reveals a second endocrine-cell population
within the focal lesion which is not exclusively com-
posed of b-cells. The focus is poorly delimited, but an
organoid pattern remains, suggesting an abnormal devel-
opmental process more than a tumor as it does not
invade or push the margins, and there is no pseudocap-
sule. The area of abnormal pancreatic development is
multilobular and can have satellites in the nearby pan-
creas that necessitate intraoperative margins analysis to
ensure complete excision and avoid recurrence [26-28].
Diffuse form means a disease involving every b-cell
throughout the pancreas with a variable involvement of
the islets. The islet pattern is preserved, but it contains
very active b-cells with very abundant cytoplasm and
highly abnormal nuclei 3 to 4 times the size of acinar
nuclei (Figure 2). These abnormalities vary in intensity
from one islet to another [26-28].
Atypical forms are not very well defined. The pattern
of pancreatic involvement is of the diffuse type but it is
found only in one large area of the pancreas [29]. Their
genetic basis is not yet totally elucidated but some are
caused by chromosomal mosaics.
3. Genetic classification
Two situations should be considered:
Focal islet-cell hyperplasia is associated with homo-
zygosity of a paternally inherited mutation of ABCC8 or
KCNJ11 genes in the hyperplastic pancreatic islets,
Table 1 Syndromic HI, main clinical and genetics features
Syndrome Inheritance Gene DD LGA Sk.M. Syndact HH HD&M IM FAC LQT CL Tumors CCA CA Deaf RP
BWS AD or S 11p15.5 X X X
Perlmann AR ? X X X X X
SGB XL Glypican3 X X X X X X X X X
CDG-Ia AR PMM2 X X X X
CDG-Ib AR PMI
Kabuki AD or S MLL2 X X X X
Sotos S NSD1 X X X X X X X X
Timothy AD or S CACNA1C X X X X
Costello AD or S HRAS X X X X
Ondine AD or AR PHOX2B X
Usher Ic AR USH1C X X X
The “X” indicates when the symptom can be present. AD: Autosomal Dominant; AR: Autosomal recessive; BWS: Beckwith-Wiedemann syndrome; CA: Cerebellar
Atrophy or Hypoplasia; CCA: Corpus Callosum Agenesia; CDG: Congenital Disorder of Glycosylation; CL: Cutis Laxa; DD: Developmental Delay; Deaf: Deafness; FAC:
Failure of Autonomic Control; HD&M: Heart Defect or Malformation; HH: Hemi Hypertrophy; IM: Intestine Malformation (Volvulus, ileal atresia, Meckel’s
diverticulum, intestinal malrotation); LGA: Large for Gestational Age; LQT: Long QT syndrome; RP: Retinitis Pigmentosa; SGB: Simpson-Golabi-Behmel syndrome;
Sk. M: Skeletal Malformation; S: Sporadic; Syndact: syndactyly; Tumors: higher risk for tumors; XL: × linked; 11p15.5: Imprinting abnormality or paternal disomy of
the 11p15.5 chromosomal region.
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mutation and a loss of the maternal allele with a pater-
nal isodisomy at the same locus [30-32]. Both ABCC8
and KCNJ11 genes are on chromosome 11p15.1.
Diffuse hyperinsulinism is heterogeneous in the
involved gene and the mechanism of inheritance. Table
2 summarizes the genes, modes of inheritance and his-
tological forms of isolated HI.
3a. Antenatal diagnosis
Antenatal diagnosis can be proposed in case of severe
diffuse isolated HI, when mutations are identified in a
proband. It will follow the same procedure as for other
genetic diseases with a molecular analysis on a chorionic
villies biopsy or the amniotic fluid. The clinical pheno-
type of severe diffuse HI is homogeneous in a family
(ABCC8 or KCNJ11). However, GLUD1 or HNF4A phe-
notypes may present major differences among patients
of a same family concerning the neurological pattern
and the occurrence of MODY, respectively. We don’t
consider relevant antenatal diagnosis for diazoxide-
responsive isolated HI, since an appropriate manage-
ment at birth will allow quick diagnosis and avoid severe
hypoglycemia, followed by an easy and safe subsequent
treatment with diazoxide.
3b. Genetic counselling
Four situations must be considered:
- De novo mutation: the risk of recurrence is null.
- Focal form: the risk of recurrence among the sib-
lings is almost negligible and was observed only
once [33]. The loss of heterozygosity of the paternal
mutation is a rare sporadic event, as suggested by
discordant identical twins and absence of HI in the
patients’ fathers. In case of consanguineous parents,
the paternal mutation responsible for a focal form in
a family has to be screened in the mother for the
next pregnancy, to exclude the possibility of a diffuse
HI by a homozygous mutation, inherited by each
parent [34].
- Diffuse form: the genetic counseling will depend
on the mode of inheritance. The risk of recurrence
is 25% for each new pregnancy when the disease is
recessively inherited, whereas this risk reaches 50%
when the disease is dominantly inherited.
Figure 1 Histology of the focal form of HI. Histological features of focal form (A1-A4) on frozen sections stained by toluidine blue (A1, A3,
A4) and on immunostaining with proinsuline antibody (A2). At low magnification (A1, x25; A2, x16) a modified architecture of pancreatic tissue
is observed within the focal form. The focal form is not encapsulated and is poorly delimited. It contains focal adenomatous hyperplasia of islets
(pale areas) intermingled and/or surrounded by exocrine acini (darkest area underlined by white stars) (A1 and A3). This pattern is underlined by
proinsuline showing an evident contrast between the focal lesion and normal pancreas (doted line circles). At high magnification (A3 and A4, ×
200), the focal lesion (A3) is composed of islets containing a heterogeneous population of endocrine cells of various sizes. Some of these cells
have large nuclei (arrows, A3) and large cytoplasms. By contrast, normal islets (doted line circles) observed outside the lesion have endocrine
cells of usual size without enlarged nuclei (A4).
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the causative gene, a theoretical risk for recurrence
for siblings exists, 25 or 50% according to the sus-
pected inheritance mode. Siblings must be screened
for hypoglycemia during the first few days of life to
avoid hypoglycemia related brain damage.
Diagnosis
The diagnostic criteria for HI include:
- Fasting and/or post-prandial hypoketotic hypogly-
cemia (< 2.5 - 3 mmol/l)
- Inappropriate plasma insulin levels (plasma insulin
concentration detectable) and c-peptide concomitant
Figure 2 Histology of the diffuse form of HI. Histological features of diffuse form (B1- B4) on frozen sections stained by toluidine blue (B1,
B3) or on formalin fixed paraffin embedded section stained with HES (B4) or with proinsuline antibody (B2). At low magnification (B1, x25; B2,
x16), the architecture is preserved with a normal distribution between exocrine (dark) and endocrine area (pale). At higher magnification (B3 and
B4 x200), abnormal endocrine islets contain cells with voluminous nuclei (arrows, B3) and enlarged cytoplasm. The entire pancreas is interspersed
with abnormal islets intermingled with morphologically normal islets in a variable proportion (B4). To confirm a diffuse form on extemporaneous
frozen sections, abnormal islets must be observed on biopsies sampled from at least 2 or 3 distinct areas of the pancreas.
Table 2 Summary of genetic causes of isolated HI
Gene Protein Inheritance Diazoxide-Resp. Histology Comment
KATP Channel ABCC8 SUR1 AR No F or D
AD Usually D
KCNJ11 Kir6.2 AR No F or D
Enzymes/Transporters GLUD1 GDH AD or DN Yes D HIHA syndrome
GCK GCK AD or DN Usually D MODY 2
HADH SCHAD AR Yes D
SLC16A1 MCT1 AD Usually D EIHI
UCP2 UCP2 AD Yes D
Transcription Factor HNF4A HNF4A AD or DN Yes D MODY 1
AR: autosomal recessive; AD: autosomal dominant; DN: De Novo; F: Focal Form; D: Diffuse Form; HI/HA: hyperammonemia/hyperinsulinism syndrome; EIHI:
Exercise-induced hyperinsulinism; GDH: Glutamate Dehydrgenase; GCK: Glucokinase; HADH: Hydroxy-Acyl-CoA Dehydrogenase; MCT1: Monocarboxylate
transporter 1; MODY: Maturity-onset diabetes of the young: UCP2: Uncoupling protein 2.
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undetectable at the time of hypoglycemia. In HI
patients, plasma insulin levels are not frequently
high during hypoglycemia, and they remain within
the normal range of the laboratory. However, normal
ranges of insulin levels were set with normal blood
glucose.
- An increase in blood glucose greater than 1.7
mmol/L (30 mg/dL) within 30 - 40 minutes after IM
or IV administration of 1 mg glucagon. Indeed insu-
lin promotes glycogen storage and inhibits its use.
Conversely, glucagon stimulates glycogenolysis.
When glucagon increases blood glucose, it proves
the paradoxical hepatic glycogen content despite
hypoglycemia, and it rules out the differential diag-
nosis of glycogen storage disease.
- Inappropriately low ketone bodies in plasma and
urines and low free fatty acids in plasma even for
fasting hypoglycemia (Insulin inhibits lipolysis) [35].
A major specific but inconstant diagnostic criterion is
the glucose infusion rate required to maintain blood
glucose above 3 mmol/L. A glucose infusion rate higher
than 10 mg/kg.min in a neonate proves an insulin
related hypoglycemia. This threshold decreases with age:
7 mg/kg.min in 5 years old children and 4 mg/kg.min in
adults. Indeed, most hormones (cortisol, growth hor-
mone, glucagon, epinephrine etc.) and metabolic path-
ways sustain blood glucose by stimulating hepatic
glycogenolysis and gluconeogenesis leading to a physio-
logical glucose output up to 10 mg/kg.min in neonates.
Thus, if hypoglycemias are still occurring despite higher
g l u c o s ei n f u s i o nr a t e ,t h eo n l yp o s s i b l em e c h a n i s mi s
insulin. Protein-induced hypoglycemia can be observed
in HI, especially in HI/HA syndrome (see HI/HA syn-
drome below).
Once the diagnosis of hyperinsulinemic hypoglycemias
is set, further routine evaluations are necessary to pre-
cise the etiology. Indeed, patients may present an “iso-
lated HI“ secondary to a primary disorder of insulin
secretion or a “syndromic HI“ where HI is one symp-
tom in the phenotype of a more generalized disease.
Most patients have isolated HI with no other associated
symptoms but a subtle facial dysmorphism [36]. Some
of these etiologies are screened with routine tests:
- Ammonemia: hyperammonemia may lead to the
diagnosis of HI/HA syndrome,
- Urine organic acids (high 3-OH-glutarate) and
plasma acylcarnitines (high C4-OH-carnitine), to
identify a short-chain-hydroxyacyl-CoA dehydrogen-
ase (SCHAD) deficiency.
- Clinical examination searching for dysmorphic fea-
tures (hemihypertrophy, overgrowth, fat pads,
congenital heart defects etc.) may require further
biochemical, imaging or genetics tests to confirm the
diagnosis of syndromic HI.
Syndromic HI includes (Table 1):
- Congenital Disorder of Glycosylation syndrome
type Ia and Ib [37]
- Kabuki syndrome [38]
- Costello syndrome [39]
- Thimoty syndrome [40]
- Usher syndrome type Ic [41]
- Ondine syndrome [42,43]
- Overgrowth syndromes
○ Beckwith-Wiedemann syndrome [44-46]
○ Perlman syndrome [47]
○ Simpson-Golabi syndrome
○ Sotos syndrome [48]
In the following chapters, only the management and
the genetics of isolated HI will be reviewed. The man-
agement of syndromic HI won’t be specifically
described, because they are diffuse, usually diazoxide-
responsive and require extra care for their supplemen-
tary symptoms.
Differential diagnosis
Perinatal-stress induced HI
This occurs under specific conditions and the pathophy-
siology remains unclear. It appears to be acquired and
not genetic. It lasts from several hours to 2 to 3 months
and may require transient diazoxide therapy. This entity
includes hyperinsulinemic hypoglycemia in newborns
from mother with unstable diabetes, small fetus for gesta-
tional age, neonates with fetal distress, birth asphyxia etc.
Drug-induced hyperinsulinemic hypoglycemia
- Oral antidiabetic drug (sulfonylurea, glinides, bigua-
nide, gliptine).
- Beta Blockers.
- Numerous other drugs: antiarrhythmic drugs (ciben-
zoline, disopyrapide, quinine, flécaine), LHRH analogue,
conversion enzyme inhibitor, antiviral drugs, leukocytes
growth factors, Interferon, Triptan etc.
- Munchhausen syndrome and Munchhausen by proxy
syndrome by insulin injection (high plasma insulin, low
c-peptide at the time of hypoglycemia) or by sulfony-
lurea administration (high insulinemia, high c-peptide
and presence of sulfonylurea in plasma and urine at the
time of hypoglycemia) [49].
Insulinoma
Insulinoma has an incidence of about 1/1, 000, 000 in
adults and is exceptional in children. In a recent review,
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at presentation was 47 years [50] or 25 years in case of
MEN-1 [51]. Thus, when hypoglycemia occurs during
childhood, an insulinoma must be considered.
Insulin resistance syndrome (IRS)
IRS is a defect of the target cells of insulin [11]. It leads
mostly to hyperinsulinemic hyperglycemia but also to
hyperinsulinemic fasting hypoglycemia. Two types of
IRS are described, depending on whether the cause is
genetics (type A: mutation in the insulin receptor gene
or in the post-receptor metabolic pathways) or auto-
immune (type B: anti-insulin receptor antibodies).
Proinsulinemic hypoglycemia
This exceptional condition with post prandial hypogly-
cemias was described in patients with defects in the pro-
cessing of prohormones (PCSK1 gene). Patients may
present with hyperphagia, chronic diarrhea, severe obe-
sity, hypocortisolism and hypogonadotropic hypogonad-
ism [52].
Hyperinsulin-like hypoglycemia
Non Islet cells tumor hypoglycemia (NICTH) is due to
an oversecretion of incompletely processed precursors
of IGF-2 (’big’-IGF-2) by the tumor. It mainly occurs in
solid tumors of mesenchymal and epithelial origin, but
also rarely in hematopoietic and neuroendocrine tumors
[53,54].
Hypoglycemia not related to inappropriate insulin
secretion or clearance
This category includes various endocrine and inherited
metabolic diseases.
Management
Rapid diagnosis and prompt management of hypoglyce-
mias are vital to prevent brain damage and intellectual
disability [55]. The severity of HI is evaluated by the
rate of glucose infusion required to maintain normogly-
cemia and the response to medical treatments.
Drugs
Three drugs are currently used in the treatment of HI.
-G l u c a g o nis a polypeptide hormone consisting in
29 amino acids. It is physiologically secreted by the
a-cells of the pancreatic islets to promote glycogen-
olysis [20]. Glucagon is essential as an emergency
treatment of severe hypoglycemia but it is not
appropriate as a long-term treatment.
-D i a z o x i d eis an antihypertensive antidiuretic ben-
zothiadiazine. Its acti o no nt h ep a n c r e a t i cb-cells
opens the KATP channel, thereby inhibiting insulin
secretion [56]. Oral diazoxide is used at the initial
dose of 5-15 mg/kg.day (neonates) or 10 mg/kg.day
b.i.d or t.i.d [57]. Later dose adjustments may be
necessary, based on its ability to maintain euglyce-
mia. Tolerance to diazoxide is usually good. The
most frequent adverse effect is hypertrichosis, which
can sometimes be marked and distressing in young
children, but will be reversible after this treatment
disruption. Hematological side effects are very rare
with the usual doses. Severe adverse effects were
observed: sodium and fluid retention may precipitate
congestive heart failure in patients with compro-
mised cardiac reserve, but usually responds to diure-
tic therapy. Moreover, life-threatening episodes of
pulmonary hypertension were observed in some neo-
nates receiving diazoxide [58]. These heart and vas-
cular complications are mostly observed in preterm
children, raising the question of its contraindication
in premature patients.
- Somatostatin analogues. Octreotide is proposed in
case of non-responsiveness to diazoxide [59]. It is
administered SC (injections/6 to 8 hours or continu-
ously with a pump) or IV because of its short half
life (1 to 2 hours). Tachyphylaxis may limit the effi-
ciency of octreotide. It leads to a rapid decrease in
t h er e s p o n s et oo c t r e o t i d e2 4 - 4 8h o u r sa f t e ri n i t i a -
tion of this treatment. As a consequence, the
response to octreotide can be assessed only 2 days
after the initiation of a new daily dose. In case of
unresponsiveness, a higher dose may be tried. The
maximal dose ranges between 15 and 50 μg/kg.d
according to the HI referent centers. Most side
effects occur just at initiation of the treatment:
vomiting and/or diarrhea and abdominal distension,
that resolve spontaneously within 7-10 days. How-
ever, fatal necrotizing enterocolitis has also been
reported in some neonates [60]. Gallbladder sludge
or stones are rare long term complications which
should be screened with abdominal ultrasounds.
Ongoing studies on long-acting somatostatin analo-
gues investigate their effectiveness and their impact
on the patients’ quality of life, in different HI refer-
ent centers in the world.
Medical management (Figure 3 and 4)
In neonates, the treatment must be diligently and inten-
sively performed to prevent irreversible brain damage
[55]. This chapter will focus on the management of
severely hypoglycemic neonates but the protocol should
be lightened for less severe patients.
Stabilization
In case of severe hypoglycemia, 1 mg Glucagon is used
IM, IV or SC, until a (central) IV line is set for
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cose may exceed the gastrointestinal tolerance of neo-
nates, so that continuous IV glucose infusion will be
associated to continuous feeding [61]. It is important to
determine the minimum glucose infusion rate required
to maintain normoglycemia both for diagnosis purpose
(a rate > 10 mg/kg.min is a specific diagnostic criteria
for HI) and to limit fluid infusion/retention. Continuous
IV glucagon (1 to 2 mg per day) can be added when
blood glucose remains unstable despite a high glucose
infusion rate. The severity of hypoglycemia or the rate
of glucose required to maintain normoglycemia cannot
foretell the form of HI: transient, genetic, focal or
diffuse.
Treatment initiation
When the diagnosis is set without any spontaneous
improvement within the first few days of life (most tran-
sient HI: e.g. gestational diabetes), a specific treatment
of HI must be initiated. Diazoxide is started for a 5 days
trial. Diazoxide responsiveness criteria is the absence of
hypoglycemia (> 3 - 3, 8 mmol/L) under a normal diet
and during a 8-12 hr fast. If diazoxide does not meet
these criteria, octreotide is added and the patient is
screened for focal forms of HI (genetic testing and PET
scan). Octreotide is started at an initial dose of 5-10 μg/
kg.d, and its response will be assessed 48 hours later.
When unresponsive, the dose will be slowly titrated up
to 15 - 50 μg/kg.d depending on the standard of care of
the HI reference center. The criteria for a fully respon-
sive patient to octreotide are the same as for diazoxide.
In case of response to medical therapy
Patients can experience spontaneous clinical improve-
ments that occur relatively early (within several months)
or later (several years). Medications can be disrupted
during childhood for most patients; however some may
still require diazoxide or octreotide for decades. The
need for a long term therapy does not apply to perina-
tal-stress induced HI.
In case of unresponsive or partially responsive HI
Glucose must be provided to maintain normoglycemia.
This may require frequent glucose enriched oral feed-
ings, frequent or continuous enteral feedings and
Figure 3 Diagnostic tree for HI. AD: Autosomal Dominant; AR: Autosomal Recessive; MODY: Maturity Onset Diabetes of the Youth; HI:
Hyperinsulinism; OAC: Organic Acid Chromatography; EIHI: Exercise-Induced HyperInsulinism; SGA: Small for gestational age. T2D: Type 2
diabetes.
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Page 8 of 14continuous IV glucose infusion. Diazoxide and/or
octreotide can be continued when a partial response
was observed.
As patients with severe HI can experience sponta-
neous, but partial improvement within the first months
of life, the surgical indication must be carefully
discussed.
Diagnosis of focal vs. diffuse HI (PET-scan and Genetics)
Precise genetic and PET-scan diagnosis are essential in
the management of diazoxide-unresponsive patients
[62-64], because:
- Close to 50% of diazoxide-unresponsive patients have
focal forms for which limited surgery may lead to total
healing with minor risk of complications [64,65].
- Some severe HI patients remain unstable with per-
sistent hypoglycemia despite an intensive medical
treatment. Subtotal pancreatectomy can be consid-
ered to reduce the risk of brain damage due to
recurrent hypoglycemia.
- Genetics and PET-scan provide informations:
○ for the diagnosis of focal or diffuse form of HI,
thus participating in the indication of surgery,
○ to determine the type of surgery: partial pan-
createctomy in case of a focal form or subtotal
pancreatectomy for diffuse HI [66-70].
18F-fluoro-L-DOPA positron emission tomography (PET)
18F-fluoro-L-DOPA PET diagnoses 75% of focal cases
and is 100% accurate in identifying the location of the
lesion [28,71-76]. The precision seems better when the
PET imaging is fused with a CT-angiography (Figure 5).
A 4 hr fast is recommended prior to the PET study to
avoid interference with bile secretion, as fluoro-DOPA is
excreted through the kidneys and in the bile.
Genetics (see section above)
The diagnosis of diffuse form is definitive when two
mutations are found in ABCC8 or KCNJ11 genes, or
mutation(s) in the other genes involved in HI. In that
case, PET-scan is not necessary.
Figure 4 Management tree for HI patients. DZX: Diazoxide; HI: Hyperinsulinism; Med treatt: Medical treatment. * Failure of the surgery for a
focal form of HI is rare, but happens when the focal form is very large or when two focal forms coexist within the same pancreas.
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Page 9 of 14A focal form is suspected only when one paternally
inherited mutation is discovered in the ABCC8 or
KCNJ11 gene. However, genetics alone may not be diag-
nostic for the focal form since i) a second mutation may
have been missed, and ii) a recent publication reports
several diffuse HI patients (histological confirmation)
carrying a single heterozygous mutation, mostly pater-
nally-inherited [6]. Thus, in patients carrying a single
KATP channel mutation, genetic analysis must be con-
fronted with the PET imaging to categorize the form of
HI, diffuse or focal.
Surgical treatment
Surgery is recommended in case of a focal form but is
required when medical and dietary therapies are ineffec-
tive to maintain normoglycemia. The indication for sur-
gery in case of severe diffuse HI may vary according to
the experience of each center. It is recommended to
stop all medications before the intervention (5 days for
diazoxide, 2 days for octreotide) as these drugs may
interfere with the histological analysis. The first step of
the intervention is to confirm the diagnosis of focal or
diffuse form of HI by performing biopsies of the head,
body and tail of the pancreas.
Once the confirmation is given:
- In case of a focal form (normal biopsies, unless one
sampled directly from the suspected focal form), the
lesion will be excised. Per operative histology will
search for abnormal cells at the margins. If so, addi-
tional resections will be performed until the margins
are clear. The patient will be totally cured without
major complication. Persistent hypoglycemia imme-
diately after surgery may account for an incomplete
resection or an exceptional distinct second focal
Figure 5 Abdominal
18F-fluoro-L-DOPA PET-scan imaging in HI. Focal form (A, B, C): PET-scan localizes accurately the focal lesion. A: Anterior
view of a 3 dimensions CT-scan reconstruction fused with PET imaging. B: Transversal view (Fusion PET&CT) of the same patient with a focal
form. The pancreatic uptake of the radiotracer is almost exclusively located at the head of the pancreas with a near-complete silencing of the
rest of the pancreatic tissue (C: Transversal PET imaging). In a suspected diffuse form, the uptake of the radiotracer appears in the whole
pancreas (D: PET, transversal view; E: Pet and 3D CT fusion). Fluoro-DOPA is excreted in the kidneys and the bile, so that liver (C, D, E), kidneys
(D, E), ureteras, bladder and diaper (E) appear on the PET imaging.
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Page 10 of 14form in the same patient. In our series of 15 patients
operated for a focal form over the last three years, 2
patients required a second surgery either because of
persistent abnormal b-cells at the margins of a very
large focal form (1 patient), or because of a co-exist-
ing and distinct 2
nd or 3
rd focal form in the same
patient (1 patient). Despite the 2
nd intervention,
these two patients have still hypoglycemias and thus
continue an intensive medical treatment.
- Diffuse form: histology shows abnormal b-cell
nuclei in all sections of the pancreas. Diffuse HI
requires near total pancreatectomy (95 - 98% of the
pancreas) leaving just the small triangle of pancreatic
tissue spanning from the duodenum to the common
bile duct. The immediate post surgical outcome is
unpredictable: disturbancei ng l u c o s eh o m e o s t a s i s
still remains (persistent hypoglycemia in about 50%
of patient, insulin-requiring diabetes in 20% of
patients during the post-surgical period) but usually
i nam o r em a n a g e a b l em a n n e rt h a nb e f o r es u r g e r y .
Pancreatic exocrine insufficiency will be treated with
pancreatic enzymes.
Particular case: HI/HA syndrome
Patients with HI/HA syndrome requires a long term
treatment with diazoxide. However, a restricted protein
diet, limiting the leucine intake to 200 mg per meal, is
possible as an adjuvant treatment.
Long-term outcome
Severe brain damage is the consequence of deep and
prolonged hypoglycemias presenting as coma and/or
status epilepticus in neonates (Figure 6, Brain RMI:
Typical lesion of severe hypoglycemia). In older chil-
dren, hypoglycemias are usually less severe and brain
damage is less frequent. Psychomotor skills and neurolo-
gical disabilities were studied in a series of 90 HI
patients (among them 63 had surgery). An intellectual
disability was observed in 26% of the patients; the deficit
was severe in 8% of them.
Major intellectual disability was more frequent:
- in neonatal-onset patients: 11% vs. 3% when HI
was diagnosed later in infancy.
- in patients who underwent surgery: 10% vs. 4%
when HI required no surgery. Within the operated
group, there was no difference between patients with
focal and diffuse forms.
In patients with moderate disability, there was no dif-
ference according to the age at onset of symptoms, the
medical or surgical treatment or the type of histological
lesion [77-79].
Patients with HI/HA syndrome have a different out-
come. Indeed, half the patients with HI/HA syndrome
have a progressive intellectual deficit and/or epilepsy
unrelated to hypoglycemia. Thus, follow-up should
include EEG with photopic stimulation and evaluations
of motor and intellectual performances [80].
Glucose intolerance and diabetes are also long term
complications of HI, especially in patients with a muta-
tion in HNF4A gene or those who underwent a near-
total pancreatectomy. In the latter, an insulin therapy
for diabetes was started in 91% of the patients within 14
years after surgery (personal data). Thus, their follow-up
must include a regular assessment of glucose tolerance
as diabetes can appear only several years after surgery.
Perspectives for future
The management of severe HI patients is challenging
and requires a multi disciplinary team: clinicians, physi-
cians, surgeons, pathologists, geneticists and basic scien-
tists. Three main themes are the focus of research:
1) to improve the medical treatment of HI when not
cured by surgery. Some new treatments are under eva-
luation (exendin (9-39) [81], long acting somatostatin
analogues). Calcium-channel blockers, like nifedipine,
showed a clear efficiency in mouse models [82] and in
isolated case reports [83,84], but most HI centers,
including ours, never observed any response to nifedi-
pine in large series of patients. Its use should be further
Figure 6 Cerebral RMI: Brain damage after severe
hypoglycemia in HI. A, B, C: Brain RMI of a patient with severe
necrotic lesions of the occipital lobes, but also cysts of parietal
lobes. D (Flair sequence): Another patient presenting with a
characteristic unilateral occipital lesion.
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Page 11 of 14evaluated to determine whether some specific indica-
tions can be retained.
2) to improve the accuracy of the diagnosis and of the
characteristics (localization and size) of focal forms.
DOPA-PET is very accurate in locating the focal form,
however for many patients, it may lack in sensitivity.
The use of new radiotracers, more specific to the hyper-
secreting b-cells may improve the accuracy and the sen-
sitivity of this preoperative test. In the operation theater,
the challenge is to better locate the focal lesion and to
perform the most selective surgery. Peroperative tests,
such as pancreatic ultrasonography, are under evaluation
[85]
3) to search for new genes involved in HI: About 50%
of diazoxide-responsive and 20% of diazoxide-unrepon-
sive patients have no genetic explanation for their dis-
ease. Families of patients are actually being studied to
bring light on the mechanisms of HI. Candidate genes
are various and may involve genes such as glucose
transporters, enzymes involved in energy metabolism
(glycogenolysis or mitochondrial modulators), transcrip-
tion factors, ion channels etc.
At last, treatment strategies differ greatly among teams
worldwide because of the lack of data about the long
term neurological and glycemic outcome of patients
according to the type of management (surgery or inten-
sive medical treatment). There are also no precise data
about the clinical remission some patients can experi-
ence and its possible mechanisms (adaptation of the
energy metabolism of the b-cells or of counter-regula-
tion hormones, premature apoptosis of the hyper-secret-
ing b-cells ...). Further collaborative studies and an
international database may certainly help for a better
understanding of the disease and to set up an interna-
tional therapeutic consensus.
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